本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

LAVA Therapeutics N.V.

1.51
-0.0200-1.31%
盤後1.510.00000.00%16:10 EDT
成交量:34.15萬
成交額:52.08萬
市值:3,972.10萬
市盈率:-1.43
高:1.55
開:1.53
低:1.50
收:1.53
52周最高:2.09
52周最低:0.8502
股本:2,630.53萬
流通股本:1,022.19萬
量比:2.91
換手率:3.34%
股息:- -
股息率:- -
每股收益(TTM):-1.0538
每股收益(LYR):-0.9359
淨資產收益率:-90.19%
總資產收益率:-21.30%
市淨率:1.99
市盈率(LYR):-1.61

資料載入中...

2022/12/23

[修訂]年度報告

20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/12/12

SEC問詢函

CORRESP [Cover] - Correspondence
2022/10/03

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/09/30

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/04/20

SEC問詢函

CORRESP [Cover] - Correspondence
2022/03/24

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/05/28

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2021/04/08

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/04/08

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/03/31

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/03/31

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/03/31

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/03/24

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/03/23

SEC問詢函

CORRESP [Cover] - Correspondence
2021/03/22

SEC問詢函

CORRESP [Cover] - Correspondence
2021/03/22

SEC問詢函

CORRESP [Cover] - Correspondence
2021/03/18

SEC問詢函

CORRESP [Cover] - Correspondence
2021/03/18

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/03/10

SEC問詢函

CORRESP [Cover] - Correspondence